Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Collegium Pharmaceutical (COLL) Liabilities and Shareholders Equity (2016 - 2025)

Historic Liabilities and Shareholders Equity for Collegium Pharmaceutical (COLL) over the last 10 years, with Q3 2025 value amounting to $1.6 billion.

  • Collegium Pharmaceutical's Liabilities and Shareholders Equity fell 170.17% to $1.6 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $6.5 billion, marking a year-over-year increase of 3131.43%. This contributed to the annual value of $1.7 billion for FY2024, which is 4550.68% up from last year.
  • Latest data reveals that Collegium Pharmaceutical reported Liabilities and Shareholders Equity of $1.6 billion as of Q3 2025, which was down 170.17% from $1.6 billion recorded in Q2 2025.
  • Collegium Pharmaceutical's Liabilities and Shareholders Equity's 5-year high stood at $1.7 billion during Q4 2024, with a 5-year trough of $646.1 million in Q1 2021.
  • Over the past 5 years, Collegium Pharmaceutical's median Liabilities and Shareholders Equity value was $1.2 billion (recorded in 2022), while the average stood at $1.2 billion.
  • Per our database at Business Quant, Collegium Pharmaceutical's Liabilities and Shareholders Equity soared by 9288.17% in 2022 and then plummeted by 1322.37% in 2024.
  • Over the past 5 years, Collegium Pharmaceutical's Liabilities and Shareholders Equity (Quarter) stood at $692.1 million in 2021, then soared by 69.65% to $1.2 billion in 2022, then decreased by 2.63% to $1.1 billion in 2023, then surged by 45.51% to $1.7 billion in 2024, then fell by 3.38% to $1.6 billion in 2025.
  • Its last three reported values are $1.6 billion in Q3 2025, $1.6 billion for Q2 2025, and $1.6 billion during Q1 2025.